Thermo Fisher Scientific Inc. (TMO) Stock Price & Analysis
Thermo Fisher Scientific Inc. (TMO) rose 5.20% to USD 494.07 as of June 9, 2026 at 22:34 UTC, according to Nexqual real-time market data.
TMO last closed at USD 469.63; the session ranged USD 473.39–494.36 on volume of 1,903,773 shares. Market capitalization is $183.61B, with a 52-week range of USD 385.46–643.99 (NYQ). Source: Nexqual, June 9, 2026 at 22:34 UTC.
Key Statistics (as of June 9, 2026 at 22:34 UTC)
| Price | USD 494.07 |
|---|---|
| Change | ▲ 5.20% (up) |
| Previous Close | USD 469.63 |
| Open | USD 473.48 |
| Day Range | USD 473.39 – 494.36 |
| 52-Week Range | USD 385.46 – 643.99 |
| Volume | 1,903,773 shares |
| Market Cap | $183.61B |
| Exchange | NYQ |
Technical Analysis (TMO)
Nexqual's technical model rates TMO "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 9, 2026 at 22:34 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 55.98 (neutral) |
| vs SMA50 | Above (USD 479.66) |
| MACD | 2.71 (positive) |
Analyst Ratings (TMO)
Wall Street analysts rate TMO "Strong Buy" based on 25 analysts, with a mean price target of USD 602.76 (range USD 490–750), per Nexqual as of June 9, 2026 at 22:34 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 25 |
| Mean Target | USD 602.76 |
| High Target | USD 750 |
| Low Target | USD 490 |
| Buy / Hold / Sell | 23 / 4 / 0 |
Earnings (TMO)
| Next Earnings Date | 2026-07-22 |
|---|---|
| EPS Estimate | USD 5.72 |
| Revenue Estimate | $11.70B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 5.44 vs est 5.24 ▲ beat |
| 2025-12-31 | USD 6.57 vs est 6.45 ▲ beat |
| 2025-09-30 | USD 5.79 vs est 5.5 ▲ beat |
| 2025-06-30 | USD 5.36 vs est 5.23 ▲ beat |
Source: Nexqual, June 9, 2026 at 22:34 UTC.
Financials & Fundamentals (TMO)
| Total Revenue | $45.20B |
|---|---|
| Revenue Growth (YoY) | +6.20% |
| Gross Margin | +40.93% |
| Operating Margin | +17.89% |
| Profit Margin | +15.15% |
| ROE | +13.52% |
| Debt / Equity | 82.9 |
| Current Ratio | 1.53 |
| Total Cash | $3.26B |
| Total Debt | $43.16B |
| Free Cash Flow | $5.52B |
Source: Nexqual, June 9, 2026 at 22:34 UTC.
Financial Health Score (TMO)
Nexqual rates Thermo Fisher Scientific Inc.'s overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 22:34 UTC.
| Growth | Mixed — Revenue +3.9% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 41%, operating 18% |
| Balance Sheet | Mixed — $3.26B cash vs $43.2B debt |
| Cash Flow | Solid — FCF $5.52B, 12% margin |
| Efficiency | Mixed — ROE 14%, ROA 5.0% |
Ownership (TMO)
| Insider Ownership | +0.15% |
|---|---|
| Institutional Ownership | +94.31% |
| Shares Outstanding | 371.62M |
| Float | 370.67M |
| Short % of Float | +1.29% |
Source: Nexqual, June 9, 2026 at 22:34 UTC.
Leadership (TMO)
Thermo Fisher Scientific Inc. is led by Marc N. Casper (age 57), Chairman & CEO, per Nexqual as of June 9, 2026 at 22:34 UTC.
| Chairman & CEO | Marc N. Casper (age 57) |
|---|---|
| President, COO & President of Products and Technologies | Gianluca Pettiti (age 46) |
| Senior VP & CFO | James R. Meyer (age 45) |
| Chief Scientific Officer | Karen E. Nelson |
| Vice President of Investor Relations | Rafael Tejada |
Major Backers & Investors (TMO)
Notable institutional backers of Thermo Fisher Scientific Inc. include Morgan Stanley, FMR, LLC, Fidelity, according to Nexqual as of June 9, 2026 at 22:34 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 2.92% |
| FMR, LLC | 2.9% |
| Fidelity | 1.98% |
| Franklin Resources, Inc. | 1.83% |
| JPMorgan | 1.83% |
| Capital Group | 1.79% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 13.76% |
| BlackRock | 9.5% |
| State Street | 5.71% |
| Geode Capital | 2.26% |
Source: Nexqual, June 9, 2026 at 22:34 UTC.
From Thermo Fisher Scientific Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Department of Health and Human Services (the DHHS), the European Medicines Agency (the EMA), the EU member states and other comparable agencies and, in the future, any changes to such laws and regulations could adversely affect us.
- We also depend in part on our trademarks and the strength of our proprietary brands, which we consider important to our business.
- Patents may not be issued for any pending or future patent applications owned by or licensed to us, and the claims allowed under any issued patents may not be sufficiently broad to protect our technology.
- In addition, competitors may design around our technology or develop competing technologies.
Partnerships
- In addition, we have availability to borrow under a revolving credit facility that provides for up to $5.00 billion of unsecured multi-currency revolving credit (the Facility).
- On November 6, 2025, the Board of Directors authorized the repurchase of up to $5.00 billion the company's common stock.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DHR | Danaher Corporation | USD 188.41 | ▲ 2.23% |
| SYK | Stryker Corporation | USD 314.01 | ▲ 2.73% |
| ZTS | Zoetis Inc. | USD 82.2 | ▲ 3.47% |
| BDX | Becton, Dickinson and Company | USD 152.04 | ▲ 0.58% |
| ISRG | Intuitive Surgical, Inc. | USD 426.61 | ▲ 1.08% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 22:34 UTC. This page is informational and not investment advice.